PeerCurrent.com|Stay current with the people and research shaping what comes next.

Your Feed AI Summary Saved Board Expert Discussion This Week in Your Field

Follows Journals Trials Guidelines Markets

Researcher

Guillaume Luxardi

UC Davis Health, Department of Ophthalmology, Sacramento, CA, USA.

1 development in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

For You Latest Breakthroughs Trials Reviews Guidelines

Latest

Everything in the corpus, newest first.

SEP 2, 2026 · JOURNAL ARTICLE

A phase II multi-institutional single arm trial evaluating TG4010 vaccine plus nivolumab in non-small cell lung cancer.

Oncoimmunology

Early-phase single-arm trial terminated early due to slow accrual with only 13 enrolled patients, showing limited clinical benefit (8.3% response rate) but providing mechanistic insights into immune response that warrant further investigation.

PreliminaryLung Neoplasms Arta M Monjazeb Immune Checkpoint Inhibitors

Reported

Sample size enrolled13

Target accrual29

Response rate1 of 12 (8.3%)

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support